Evidence map›Paper›PMID 42638513›Full record

ArticleChemMedChem2026

Iso- and Benzisothiazolinone Inhibitors of Monoacylglycerol Lipase: Exploring On-Target Activity Through Scaffold Decoration and In Situ Warhead Generation.

Edoardo Rocca, Annalida Bedini, Laura Scalvini, Francesca Galvani, Riccardo Castelli, Lorenzo Sarcone, Adriano Recchia, Fabiola Fanini, Adren Tran, Silvia Rivara and 3 more

Abstract read
In one paragraph

Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Edoardo RoccaDipartimento di Scienze degli Alimenti e del Farmaco, Università degli Studi di Parma, Parma, Italy.ORCID https://orcid.org/0009-0004-4364-3409
Annalida BediniDipartimento di Scienze Biomolecolari, Università degli Studi di Urbino "Carlo Bo", Urbino, Italy.ORCID https://orcid.org/0000-0002-9103-2918
Laura ScalviniDipartimento di Scienze degli Alimenti e del Farmaco, Università degli Studi di Parma, Parma, Italy.ORCID https://orcid.org/0000-0003-3610-527X
Francesca GalvaniDepartment of Anatomy and Neurobiology, University of California, Irvine, California, USA.
Riccardo CastelliDipartimento di Scienze degli Alimenti e del Farmaco, Università degli Studi di Parma, Parma, Italy.ORCID https://orcid.org/0000-0002-5149-435X
Lorenzo SarconeDipartimento di Scienze degli Alimenti e del Farmaco, Università degli Studi di Parma, Parma, Italy.ORCID https://orcid.org/0009-0004-9605-0498
Adriano RecchiaDipartimento di Scienze Biomolecolari, Università degli Studi di Urbino "Carlo Bo", Urbino, Italy.ORCID https://orcid.org/0009-0000-9536-252X
Fabiola FaniniDipartimento di Scienze Biomolecolari, Università degli Studi di Urbino "Carlo Bo", Urbino, Italy.ORCID https://orcid.org/0000-0002-8392-2881
Adren TranDepartment of Anatomy and Neurobiology, University of California, Irvine, California, USA.ORCID https://orcid.org/0009-0004-0671-7202
Silvia RivaraDipartimento di Scienze degli Alimenti e del Farmaco, Università degli Studi di Parma, Parma, Italy.ORCID https://orcid.org/0000-0001-8058-4250
Gilberto SpadoniDipartimento di Scienze Biomolecolari, Università degli Studi di Urbino "Carlo Bo", Urbino, Italy.
Daniele PiomelliDepartment of Anatomy and Neurobiology, University of California, Irvine, California, USA.
Marco MorDipartimento di Scienze degli Alimenti e del Farmaco, Università degli Studi di Parma, Parma, Italy.ORCID https://orcid.org/0000-0003-0199-1849

Funding

Allosteric control of monoacylglyceride lipase (MGL) activityR21DA053358 · NIDA · UNIVERSITY OF CALIFORNIA-IRVINE · PI MOR, MARCO, PIOMELLI, DANIELE · 2022 to 2023
$397k
NIDA NIH HHS R21 DA053358NIH DA053358
6 · The paper itself

Abstract

Monoacylglycerol lipase (MGL) is an intracellular serine hydrolase that regulates endocannabinoid signaling by hydrolyzing 2-arachidonoylglycerol (2-AG), thereby controlling cannabinoid receptor activity and related physiological processes. Targeting MGL through allosteric mechanisms is a promising strategy to modulate 2-AG levels while avoiding limitations associated with active site-directed inhibitors. In this study, we aimed to develop selective MGL inhibitors based on isothiazolinone (ITZ) and benzisothiazolinone (BTZ) scaffolds that covalently target the regulatory cysteine residues Cys201 and Cys208 forming disulfide adducts. Two complementary approaches were explored. First, a mechanism-based strategy was designed to exploit MGL-mediated hydrolysis of O-substituted (benz)isothiazol-3-ol derivatives, enabling localized release of the reactive warhead in proximity to the target cysteines. Second, to enhance molecular recognition, tailored substituents were introduced on the BTZ scaffold to promote selective interactions with residues surrounding the allosteric site. Although several compounds displayed nanomolar inhibitory activity, structure-activity relationship analysis indicated that inhibitory potency is primarily driven by intrinsic warhead reactivity rather than specific protein-ligand interactions. Overall, these findings highlight both the potential and the challenges of developing selective covalent allosteric MGL inhibitors, emphasizing the need for strategies that better balance reactivity and molecular recognition.

Indexed as

Enzyme InhibitorsMonoacylglycerol LipasesThiazolesDose-Response Relationship, DrugHumansMolecular StructureStructure-Activity Relationship1,2-benzisothiazoline-3-oneEnzyme InhibitorsisothiazolidinoneMonoacylglycerol LipasesThiazolesallosteric regulationbenzisothiazolinonedrug designendocannabinoid systemmedicinal chemistrymonoacylglycerol lipase

Identifiers

PMID42638513
PMCPMC13504407

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.